A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).

被引：0
|
作者：
Karzai, Fatima H.
Madan, Ravi Amrit
Apolo, Andrea Borghese
Parnes, Howard L.
Wright, John Joseph
Trepel, Jane B.
Beatson, Melony A.
Harold, Nancy
Couvillon, Anna
Steinberg, Seth M.
Price, Douglas K.
Gulley, James L.
Figg, William Douglas
Dahut, William L.
机构：
[1] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
[2] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Bethesda, MD 20892 USA
[4] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[5] NCI, Rockville, MD USA
[6] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5095
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Karnes, R. Jeffrey
    Ahmed, Mohamed E.
    APPLIED RADIOLOGY, 2021, 50 (01) : 42 - 43
  • [22] Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure
    Green, Angela K.
    Corty, Robert W.
    Wood, William A.
    Meeneghan, Mathew
    Reeder-Hayes, Katherine E.
    Basch, Ethan
    Milowsky, Matthew I.
    Dusetzina, Stacie B.
    ONCOLOGIST, 2015, 20 (05): : 516 - 522
  • [23] Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
    Thomson, Alastair
    Pollard, Adam
    Mark, Frances May
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [24] Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts)with metastatic castration-resistant prostate cancer (mCRPC)
    Huang, X.
    Ning, Y. M.
    Gulley, J. L.
    Kluetz, P. G.
    Adelberg, D.
    Mulquin, M.
    Madan, R. A.
    Bassim, C.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [25] Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Huang, X.
    Ning, Y. M.
    Mulquin, M.
    Madan, R. A.
    Gulley, J. L.
    Kluetz, P. G.
    Adelberg, D.
    Arlen, P. M.
    Parnes, H. L.
    Adesunloye, B.
    Steinberg, S. M.
    Wright, J. J.
    Trepel, J. B.
    Chen, C.
    Bassim, C.
    Apolo, A. B.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naive, metastatic, castrate-resistant prostate cancer(CRPC)
    De Souza, P. L.
    Mellado, B.
    Pfister, C.
    Rosenthal, M.
    Castellano, D. E.
    Weber, D.
    Ferrara, S.
    Shaik, N.
    Tan, E.
    Patterson, S. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA plus P)
    Lozano Mejorada, R.
    Romero Laorden, N.
    Jayaram, A.
    Lopez, F.
    Saez, M. I.
    Villatoro, R.
    Montesa, A.
    Moreno, I.
    Ruiz Vico, M.
    Garcia Ferron, M.
    Rogado, J.
    Cendon Florez, Y.
    Nombela Blanco, P.
    Rivera, L.
    Grau, G.
    Cruz Hernandez, J. J.
    Lorente Estelles, D.
    Attard, G.
    Castro Marcos, E.
    Olmos Hidalgo, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
    Smith, Matthew Raymond
    De Bono, Johann Sebastian
    Sternberg, Cora N.
    Le Moulec, Sylvestre
    Oudard, Stephane
    De Giorgi, Ugo
    Krainer, Michael
    Bergman, Andre M.
    Hoelzer, Wolfgang
    De Wit, Ronald
    Boegemann, Martin
    Saad, Fred
    Cruciani, Giorgio
    Thiery-Vuillemin, Antoine
    Feyerabend, Susan
    Miller, Kurt
    Ramies, David Albert
    Hessel, Colin
    Weitzman, Aaron
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [29] Phase II trial of circulating cytokines as markers of docetaxel (DTX) resistance in metastatic castrate resistant prostate cancer (mCRPC).
    Mahon, Kate Lynette
    Lin, Hui-Ming
    Spielman, Calan
    Lee-Ng, Michelle
    Gurney, Howard
    Mallesara, Girish
    Stockler, Martin R.
    Briscoe, Karen P.
    Marx, Gavin M.
    Breit, Samuel N.
    Brown, David A.
    Horvath, Lisa
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] PHASE II TRIAL OF CIRCULATING CYTOKINES AS MARKERS OF DOCETAXEL RESISTANCE IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (mCRPC)
    Mahon, Kate
    Lin, H-M
    Spielman, C.
    Lee-Ng, M.
    Gurney, H.
    Mallesara, G.
    Stockler, M.
    Briscoe, K.
    Marx, G.
    Breit, S. N.
    Brown, D.
    Horvath, L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 37 - 37
12345